WHITEHAWK THERAPEUTICS, INC. Costs and Expenses
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Costs and Expenses of $18.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-06-30 was $18.11M, a 66.92% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-03-31 was $23.52M, a 5.18% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-12-31 was $24.89M, a 4.97% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-09-30 was $19.55M, a 5.23% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for fiscal 2025 was $121.55M, a 30.08% increase from fiscal 2024.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for fiscal 2024 was $93.44M, a 2.96% decline from fiscal 2023.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for fiscal 2023 was $96.29M, a 23.61% increase from fiscal 2022.
- WHITEHAWK THERAPEUTICS, INC. costs and expenses for fiscal 2022 was $77.90M, a 30.66% decline from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.11M 10-Q · filed 2026-08-06 | $41.63M 10-Q · filed 2026-08-06 | $66.52M derived: sum of 3 quarters · filed 2026-08-06 | $86.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $23.52M 10-Q · filed 2026-05-07 | $48.41M derived: sum of 2 quarters · filed 2026-05-07 | $67.95M derived: sum of 3 quarters · filed 2026-05-07 | $122.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $24.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $44.43M derived: sum of 2 quarters · filed 2026-03-12 | $99.18M derived: sum of 3 quarters · filed 2026-08-06 | $121.55M 10-K · filed 2026-03-12 |
| 2025-09-30 | $19.55M 10-Q · filed 2025-11-06 | $74.30M derived: sum of 2 quarters · filed 2026-08-06 | $96.66M 10-Q · filed 2025-11-06 | $122.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $54.75M 10-Q · filed 2026-08-06 | $77.11M 10-Q · filed 2026-08-06 | $103.30M derived: sum of 3 quarters · filed 2026-08-06 | $123.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $22.36M 10-Q · filed 2026-05-07 | $48.55M derived: sum of 2 quarters · filed 2026-05-07 | $69.18M derived: sum of 3 quarters · filed 2026-05-07 | $90.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $46.81M derived: sum of 2 quarters · filed 2026-03-12 | $68.58M derived: sum of 3 quarters · filed 2026-03-12 | $93.44M 10-K · filed 2026-03-12 |
| 2024-09-30 | $20.63M 10-Q · filed 2025-11-06 | $42.39M derived: sum of 2 quarters · filed 2025-11-06 | $67.25M 10-Q · filed 2025-11-06 | $91.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $21.76M 10-Q · filed 2025-08-07 | $46.63M 10-Q · filed 2025-08-07 | $70.67M derived: sum of 3 quarters · filed 2025-08-07 | $94.48M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $24.86M 10-Q · filed 2025-05-08 | $48.91M derived: sum of 2 quarters · filed 2025-05-08 | $72.71M derived: sum of 3 quarters · filed 2025-05-08 | $98.46M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $24.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $47.85M derived: sum of 2 quarters · filed 2025-03-28 | $73.59M derived: sum of 3 quarters · filed 2025-03-28 | $96.29M 10-K · filed 2025-03-28 |
| 2023-09-30 | $23.81M 10-Q · filed 2024-11-06 | $49.55M derived: sum of 2 quarters · filed 2024-11-06 | $72.25M 10-Q · filed 2024-11-06 | $92.95M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $25.75M 10-Q · filed 2024-08-07 | $48.44M 10-Q · filed 2024-08-07 | $69.14M derived: sum of 3 quarters · filed 2024-08-07 | $88.42M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $22.69M 10-Q · filed 2024-05-08 | $43.39M derived: sum of 2 quarters · filed 2024-05-08 | $62.67M derived: sum of 3 quarters · filed 2024-05-08 | $84.47M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $39.98M derived: sum of 2 quarters · filed 2024-03-13 | $61.78M derived: sum of 3 quarters · filed 2024-03-13 | $77.90M 10-K · filed 2024-03-13 |
| 2022-09-30 | $19.28M 10-Q · filed 2023-11-08 | $41.08M derived: sum of 2 quarters · filed 2023-11-08 | $57.20M 10-Q · filed 2023-11-08 | $74.14M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $21.80M 10-Q · filed 2023-08-09 | $37.92M 10-Q · filed 2023-08-09 | $54.86M derived: sum of 3 quarters · filed 2023-08-09 | $142.17M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $16.12M 10-Q · filed 2023-05-10 | $33.07M derived: sum of 2 quarters · filed 2023-05-10 | $120.38M derived: sum of 3 quarters · filed 2023-05-10 | $124.25M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $16.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $104.26M derived: sum of 2 quarters · filed 2023-03-29 | $108.13M derived: sum of 3 quarters · filed 2023-03-29 | $112.34M 10-K · filed 2023-03-29 |
| 2021-09-30 | $87.31M 10-Q · filed 2022-11-09 | $91.19M derived: sum of 2 quarters · filed 2022-11-09 | $95.39M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $3.88M 10-Q · filed 2022-08-10 | $8.08M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $4.21M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |